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ABSTRACT 
Background & Aims: Symptoms suggestive of colorectal cancer may originate outside the 
colorectum. Computed tomographic colonography (CTC) is used to simultaneously examine the 
colorectum and abdomino-pelvic organs. We performed a prospective, randomized controlled trial 
to quantify the frequency, nature, and consequences of extra-colonic findings. 
 
Methods: We studied 5384 patients from 21 UK National Health Service hospitals referred by their 
family doctor for investigation of symptoms of colorectal cancer from March 2004 through 
December 2007. The patients were randomly assigned to groups that received the requested test 
(barium enema or colonoscopy, n=3574) or CTC (n=1810). We determined the frequency and nature 
of extracolonic findings, subsequent investigations, ultimate diagnosis, and extracolonic cancer 
diagnoses 1y and 3 y after testing of patients without colorectal cancer.  
 
Results: Extracolonic pathologies were detected in 959 patients by CTC (58.7%), in 42 patients by 
barium enema analysis, (1.9%), and in no patients by colonoscopy. Extracolonic findings were 
investigated in 142 of these patients (14.2%) and a diagnosis was made for 126 patients (88.1%). 
Symptoms were explained by extracolonic findings in 4 patients analyzed by barium enema (0.2%) 
and 33 patients analyzed by CTC (2.8%). CTC identified 72 extracolonic neoplasms, whereas barium 
enema analysis found only 3 (colonoscopy found none). Overall, CTC diagnosed extracolonic 
neoplasms in 72/1634 patients (4.4%); 26 of these were malignant (1.6%). There were significantly 
more extracolonic malignancies detected than expected 1 y after examination, but these did not 
differ between patients evaluated by CTC (22.2/1000 person-y), barium enema (26.5/1000 person-y; 
P=.43), or colonoscopy (32.0/1000 person-y; P=.88).  
 
Conclusions: More than half of patients with symptoms of colorectal cancer are found to have 
extracolonic pathologies by CTC analysis. However, the proportion of patients found to have 
extracolonic malignancies after 1 year of CTC examination is not significantly greater than after 
barium enema or colonoscopy examinations.  
International Standard Randomised Controlled Trials no: 95152621. 
isrctn.com 
 
 
 
KEYWORDS: detection; diagnostic, digestive system, colon cancer 
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Introduction 
Symptoms suggestive of colorectal cancer are common and non-specific, and may originate 
from pathology outside the large bowel.
1
 Patients are often investigated with colonoscopy 
or barium enema (BE), which only image the colorectum. Computed tomographic 
colonography (CTC) is used increasingly to investigate symptomatic patients because it is 
sensitive for colorectal cancer while simultaneously examining other abdomino-pelvic 
organs. However, it is uncertain whether detection of extracolonic pathology is ultimately 
beneficial. While undoubtedly important in some patients, in others extracolonic findings 
can precipitate investigations that are costly, increase morbidity and anxiety, and are 
ultimately unnecessary. A systematic review of 3488 patients, most of whom were 
symptomatic, found that 14% underwent further investigation, yielding 2·7% extracolonic 
cancers overall.
2
 An economic analysis by the same group found that average costs incurred 
to investigate extracolonic findings exceeded costs of the initial CTC.
3
 Systematic review of 
24 studies estimated false-positive diagnoses of extracolonic malignancy by CTC in 4·6% men 
and 6·8% women.
4
 
 
The clinical impact of extracolonic findings at CTC has most often been assessed 
retrospectively,
5-7
 and the largest studies have investigated asymptomatic individuals being 
screened for colorectal cancer.
8, 9
 A systematic review by the authors found no prospective, 
randomized study examining the consequences of extracolonic detections in symptomatic 
patients in daily practice.
10
 We performed parallel pragmatic randomized controlled trials of 
CTC versus colonoscopy or BE. Detection rates for intracolonic pathology are reported 
elsewhere.
11, 12
 Here we describe the frequency and nature of extracolonic pathology 
detected by CTC, the rate and nature of subsequent investigations to investigate and/or 
treat extracolonic findings, adverse events related to investigation, and ultimate clinical 
outcome.  
 
 
Methods 
 
 
Study Design and participants 
 
The protocol for these multicentre randomized trials has been published previously
13
 and 
can be found online (http://www.hta.ac.uk/project/1366.asp). The trial is registered: 
International Standard Randomised Controlled Trials Number 95152621. 
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http://www.controlled-trials.com/ISRCTN95152621/95152621. Research nurses at 21 UK 
National Health Service (NHS) teaching and general hospitals recruited patients referred by 
their family doctor for investigation of symptoms suggestive of colorectal cancer. Patients 
were eligible if aged 55 years or older, fit to undergo full bowel purgation, had no known 
genetic predisposition to cancer, had no history of inflammatory bowel disease, had not had 
a whole-colon examination within 6 months, and were not being followed-up for previous 
colorectal cancer. We obtained demographic and baseline clinical data such as age, sex, and 
symptoms for all potentially eligible patients. The consulting clinician then decided in line 
with their usual clinical practice whether to investigate the patient using colonoscopy or BE 
(the default examinations). We created two parallel trials and, within each, patients were 
randomly assigned to the default examination or CTC.
13
 There was no overlap of patients 
between trials. We obtained ethical approval from the Northern and Yorkshire Multicentre 
Research Ethics Committee and from all participating hospitals. The trials were supervised 
by independent data monitoring and trial steering committees. All patients gave informed 
written consent. 
 
Randomization & masking 
 
We used a randomization ratio of 2:1 to receive either the default examination (BE or 
colonoscopy) or CTC. A statistician (RE) generated the randomization codes at a remote site, 
and codes were concealed until interventions were assigned. Randomization was done 
centrally by computer random number generation, in blocks of six, stratified by centre and 
patient sex. Participants and those administering the procedures were not masked to the 
assigned study intervention. 
 
Procedures 
 
Methods for CTC reflected contemporary consensus on best practice,
14
 including full bowel 
purgation and gas insufflation. Multidetector row CT scanners (minimum four rows) were 
used with maximum detector collimation of 2·5 mm and a pitch that allowed abdominal 
coverage (40 cm) within 20 seconds. Prone and supine scans were recommended. Readers 
used two-dimensional (2D) and/or three-dimensional (3D) visualization as preferred; the 
minimum requirement was primary 2D analysis with volume or surface rendering for 
problem solving. Reading platform depended on local preference, as did use of intravenous 
contrast and faecal tagging agents. Computer-assisted detection was available. 45 
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radiologists sub-specialising in gastrointestinal radiology interpreted the CTC studies. All 
radiologists were familiar with interpreting CTC, and those who had read fewer than 100 
cases, or who desired additional training, attended a supplementary 2-day course. Double-
contrast BE was undertaken after full bowel preparation and administration of an 
intravenous spasmolytic, with carbon dioxide or air for insufflation. Digital fluoroscopic 
images of the double-contrasted colorectum were obtained to the caecum, supplemented 
by overcouch decubitus films
15
. 217 gastroenterologists or colorectal surgeons undertook 
the colonoscopies
16
.  
 
For each procedure, the radiologist or endoscopist issued a report as usual that noted 
colonic lesions if present. As per normal practice, radiologists were free to describe/ignore 
any potential extracolonic lesion identified during their interpretation if they believed this 
relevant/irrelevant to the clinical situation. Referrals for additional investigation following 
the randomized procedure were made at the discretion of local clinicians in charge of the 
patient’s care based on clinical judgment informed by symptoms, clinical examination, 
procedural findings, patient status, and local practice.  
 
Research nurses collected reports from all subsequent diagnostic procedures related to the 
diagnostic episode, including surgical procedures intended to clarify and/or treat 
extracolonic findings. Referrals to investigate intracolonic pathology are described 
elsewhere.
11, 12
 Referrals to investigate extracolonic findings are described here.  
 
Outcomes 
The primary outcome for the BE trial was the detection of colorectal cancer or large (≥10 
mm) polyps, and for the colonoscopy trial was additional colonic investigation required to 
confirm or exclude such pathology.
11-13
 The rate and nature of extracolonic findings at 
randomized procedures was a pre-specified secondary outcome
13
 and such patients were 
followed up until either a diagnosis was given, the patient was placed into surveillance, or a 
decision was made not to investigate further during the diagnostic episode “on-trial”.  
 
A study researcher (ED) extracted references to extracolonic pathology from procedure 
reports into a database. Each extracolonic finding was then assigned an “E-RADS” score
17
 by 
a radiologist (SH) blind to subtrial, reporting radiologist, centre, and ultimate diagnosis. E-
RADS categorizes the perceived clinical importance of extracolonic findings as follows: E1 - 
Normal or anatomic variant, E2 - Clinically unimportant, E3 – Likely unimportant but 
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incompletely characterised, E4 – Potentially important.
17
 A data manager coded the final 
diagnosis using the ICD-10 classification. An expert panel consisting of a radiologist (SH), 
gastroenterologist (JT), and colorectal surgeon (OF) reviewed extracolonic diagnoses 
independently to establish whether these could have explained patients’ presenting 
symptoms. Specifically, the panel members were provided with a spreadsheet that detailed 
the presenting symptom(s) along with the final extracolonic diagnosis for each individual 
patient in whom such a diagnosis was made. Each panel member then made an independent 
decision as to whether, in their clinical opinion, the symptoms could have potentially been 
explained by the extracolonic finding. Panel members were blinded to the primary assigned 
randomized procedure in all cases to eliminate potential bias arising from their clinical 
specialty. If there was any disagreement, a consensus decision was reached between the 
panel members with the help of a data manager, who provided additional clinical details 
where necessary.   
 
The total number and nature of surgical procedures, non-surgical but invasive procedures, 
and non-invasive procedures used to investigate and/or treat extracolonic findings were 
determined for each of the trial arms. Unit costs for these procedures were obtained from 
the National Schedule of National Health Service costs at 2014/14 estimates. Details of 
cancer diagnoses (colonic and extracolonic) and deaths in the trial cohort were obtained 
from the NHS Information Centre (NHSIC). 
 
Statistical analysis 
Sample size calculations for the primary outcome for each trial have been described 
previously.
11-13
 We analysed extracolonic cancers by intention to treat, identifying those 
diagnosed within 36 months of randomisation. We included all reported primary malignant 
neoplasms, except colorectal cancers (ICD-10: C18–C20) and non-melanoma malignant 
neoplasms of the skin (C44). We calculated expected numbers of extracolonic cancers by 
applying age-sex-specific cancer incidence for the general population to our cohort, 
adjusting for reported mortality.
18
 We compared incidence assuming a Poisson distribution. 
Categorical outcomes were compared using Pearson’s χ
2
 test or Fisher’s exact test, as 
appropriate. We calculated relative risks (RRs) with 95% CIs. We analysed the data using 
Stata 10.1. The trial is an International Standard Randomised Controlled Trial, number 
95152621. All authors had access to the study data and reviewed and approved the final 
manuscript. 
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Results  
Recruitment began March 2004 and ceased December 2007. Our sample size was exceeded. 
Patient flow through the trial is shown in Figure 1. Of 8484 patients identified as potentially 
eligible, 3100 were excluded (2176 because of a doctor’s decision, 898 because of a patient’s 
decision, and 26 for unknown reasons) (Appendix Table 1), and 5384 were randomized 
(3804 within the BE trial and 1580 within the colonoscopy trial). After patients diagnosed 
with colorectal cancer during the study were excluded, a total of 4766 patients were 
analysed, 1634 of whom had CTC (1161 from the BE trial and 473 from the colonoscopy 
trial). In both trials, change in bowel habit was the commonest symptom (3623, 76% of all 
patients analysed), followed by abdominal pain (BE trial) and rectal bleeding (colonoscopy 
trial) (Appendix Table 2). 
 
Reporting of extracolonic findings 
Of the 1634 patients having CTC, 959 (58·7%) had at least one extracolonic finding described 
in the clinical report: 672 (57·9%) in the BE trial and 287 (60·7%) in the colonoscopy trial 
(Figure 1). 42 (1·9%) patients having BE and none having colonoscopy had an extracolonic 
finding reported. 1830 individual extracolonic findings were reported overall (Table 1): 1784 
on CTC (1246 BE trial, 538 colonoscopy trial), 46 on BE, and none on colonoscopy; 
extracolonic findings seen at BE vs. CTC are available online (Appendix Table 1); The majority 
of BE findings were related to abnormal colonic location (e.g. 18 hernias) or displacement 
(e.g. 3 cases of extrinsic compression), calcifications (3 gallstones, 2 renal stones, 4 fibroids), 
or skeletal disease (e.g. degeneration, Paget’s). 
 
There was no association between sex and reporting of an extracolonic finding; however, 
patients were significantly more likely to have an extracolonic finding reported if they were 
older (p<0.0001). In both trials the proportion of patients with at least one extracolonic 
finding reported by CTC increased with age, rising in the BE trial from 48% for those aged 55-
64 years, to 74% for those aged 85 years or over, and from 56% to 90% respectively in the 
colonoscopy trial (Table 2). 
 
Of the 1830 individual extracolonic findings reported overall (Table 1): 1390 (75·9%) were 
categorised as E2 (“clinically unimportant”); 337 (18·4%) as E3 (“likely unimportant but 
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9
incompletely characterised”); 82 (4·5%) as E4 (“potentially important”). There were 21 E1 
findings (normal anatomical variant or post-surgery appearance). E2 findings were reported 
most frequently and E4 least frequently, for both BE and CTC but the rate per 1000 patients 
was substantially higher for CTC. For example, in the BE trial E3 findings were reported for 
3·1 patients per 1000 having BE vs. 209·3 for patients having CTC (Table 1). Rates for CTC 
were similar between trials (Table 1). 
 
Subsequent investigation of extracolonic findings 
Of 1001 individual patients with an extracolonic finding reported, 142 (14·2%) patients (136 
having CTC, 6 having BE, none having colonoscopy) underwent subsequent procedures to 
investigate 144 extracolonic findings; Simple laboratory tests (e.g. blood and urine) are 
excluded from these data. Overall, 8·3% of patients having CTC eventually had an 
extracolonic finding investigated; 88 (7·6%) and 48 (10·1%) from the BE and colonoscopy 
trials respectively. Overall, 58 (76·3%) of 76 CTC findings classified as E4 were investigated 
compared to 57 (17·3%) of 330 classified as E3, and 23 (1·7%) of 1357 classified as E2 (Table 
1).  
 
The most invasive procedure used for investigation was surgical in 34 (23·6%) instances, 
invasive but non-surgical in 38 (26·4%), and non-invasive imaging in 69 (47·9%). The most 
common surgical procedures were nephrectomy (9 patients), oophorectomy (7 patients) 
and aortic aneurysm repair (5 patients). Some patients had multiple procedures (for 
example imaging followed by surgery) and surgery sometimes combined diagnosis and 
treatment (for example excision biopsy). As a result, the total number of individual 
procedures performed in the 142 patients referred was 208; surgical in 35 instances, 
invasive but non-surgical in 51, and non-invasive imaging in 122 (Appendix Table 4). 196 of 
these procedures (117 BE trial, 79 colonoscopy trial) occurred in patients randomized to CTC 
where 12 occurred in patients randomized to BE (Appendix Table 4). None occurred in 
patients randomized to colonoscopy. 
 
The total unit costs generated to investigate and/or treat extracolonic findings in the BE trial 
were 10,289 Great British Pounds (GBP) for patients randomized to BE compared with 115, 
059 GBP for patients randomized to CTC. These costs broke down as follows: For BE versus 
CTC respectively, unit costs for surgical procedures were 9,135 GBP vs. 100,740 GDP; for 
invasive non-surgical procedures, 532 GBP vs. 7,268 GBP; and for non-invasive procedures, 
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622 GBP vs. 7,051 GBP. Overall, the mean cost to investigate extracolonic findings per 
patient randomized to BE was 4.63 GBP versus 99.10 GBP for CTC.  
 
The total unit costs generated to investigate and/or treat extracolonic findings in the 
colonoscopy trial was 72,358 (GBP) for patients randomized to CTC; there were no costs 
attributable to colonoscopy since no extracolonic findings were reported. These costs broke 
down as follows: Unit costs for surgical procedures were 63,361 GBP; for invasive non-
surgical procedures, 4,243 GBP; and for non-invasive procedures, 4,754 GBP. Overall, the 
mean cost to investigate extracolonic findings per patient randomized to CTC was 152.98 
GBP versus nil for colonoscopy.  
 
Presenting symptoms and extracolonic diagnosis 
An extracolonic diagnosis was reached in 126 (88·1%) of the 142 patients undergoing 
subsequent investigation for an extracolonic finding; this explained the presenting 
symptoms in 54 (38%) (Table 2). Overall, 4 (0·2%) patients undergoing BE received an 
extracolonic diagnosis that explained their presenting symptoms vs. 33 (2·8%) undergoing 
CTC, and none undergoing colonoscopy vs. 17 (3·6%) undergoing CTC. The association 
between presenting symptoms and a subsequent extracolonic finding that explained these 
was relatively weak, being highest for patients with abdominal pain in the colonoscopy trial 
(10%) and very low for most symptoms (Table 2). 
 
There were 75 extracolonic neoplasms diagnosed, 72 of which were diagnosed by CTC (26 
malignant), 3 by BE (all malignant) and none by colonoscopy (Table 3). Taking both trials 
together, extracolonic neoplasms were diagnosed in 71/1633 (4·3%) of patients having CTC 
in whom colorectal cancer had been excluded, with extracolonic malignancy diagnosed in 25 
(1·5%) overall. The most frequent primary malignancies diagnosed by CTC were renal (7 
cases), pancreatic (3 cases), and prostate (2 cases). The most frequent benign tumours were 
ovarian (16 cases). 23 of 26 patients with an extracolonic malignancy had presenting 
symptoms that were explained by this (Table 3). 
 
Extracolonic cancers diagnosed within 1 and 3 years of randomisation 
Primary extracolonic cancers diagnosed within 1 year of randomisation are shown in Table 4 
and within 3 years of randomisation in Table 5. Kaplan-Meier plots displaying the cumulative 
incidence of extracolonic cancer in the two trials at both 1- and 3-years post-randomisation 
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are shown in Figure 2. 
 
In the first year following randomisation, rates of primary extracolonic cancer diagnosis in 
the BE trial were nearly twice as high as expected from general population rates (incidence 
rate ratio [IRR] per 1000 person years 1·88, 95%CI 1·33–2·65; p=0·0002) and were more than 
twice as high as expected in the colonoscopy trial (IRR 2·33, 1·40–3·89; p=0·0007). However, 
incidence did not differ between trial arms: 22.2 for CTC vs. 26.5 BE (IRR 0·84, 0·54–1·30; 
p=0·43) and 30.6 for CTC vs. 32.0 colonoscopy (IRR 0·95, 0·53–1·73; p=0·88). At 3-years there 
was also no difference between trial arms: 21·3 for CTC vs. 18·0 for BE (IRR 1·18, 95% CI 
0·89–1·57; p=0·24) and 17·6 for CTC vs. 18·7 for colonoscopy (IRR 0·94, 95% CI 0·59–1·49; 
p=0·79). Analysis of the Kaplan-Meier plots of the cumulative incidence of extracolonic 
cancer found no significant difference between trial arms for the BE trial and colonoscopy 
trials at both 1-year following randomization (p=0·35 and p= 0·18 respectively) and 3-years 
following randomization (p=0·97 and p=0·94 respectively) (Figure 2).  
 
Six patients died within 60 days of follow-up for an extracolonic finding: 4 died from 
metastatic disease, one died following a Whipple procedure for pancreatic carcinoma and 
one died following open repair of an aortic aneurysm. There was no significant difference in 
the proportions of patients dying within 3 years of randomisation (including those with 
colorectal cancer): 188 (7·4%) of 2527 randomized to BE vs. 107 (8·4%) of 1277 patients 
randomized to CTC (p=0·306); 86 (8·2%) of 1047 patients randomized to colonoscopy vs. 36 
(6·8%) of 533 randomized to CTC (p=0·304). 
 
Discussion 
Hara and co-workers
5
 first highlighted extracolonic detections by CTC; their retrospective 
review found that 30 (11%) of 264 consecutive patients at high risk of colorectal cancer had 
potentially important extracolonic lesions. Retrospective review of 10,286 CTC screening 
examinations found extracolonic cancer exceeded colonic (0·35% vs 0·21%).
8
 A retrospective 
study of 400 symptomatic patients found 23 extracolonic malignancies via CTC.
7
 However, a 
2009 commentary predicted a “deluge” of incidental extracolonic findings, triggering anxiety, 
expense, morbidity and mortality.
19
 Our systematic review
10
 found no randomized data 
regarding the rate of extracolonic findings nor their influence on subsequent investigation 
and ultimate diagnosis.  
 
The pragmatic design of our two parallel, multi-centre, randomized controlled trials of CTC 
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for symptomatic patients
11, 12
 allowed us to observe how reporting of extracolonic lesions 
influenced subsequent diagnostic trajectory and ultimate diagnosis. 58·7% CT reports 
described extracolonic findings, a figure similar to the 63% from a USA study of high and 
average risk patients.
20
 We found extracolonic detections rose significantly with age; a USA 
study
21
 found extracolonic abnormalities in 74% patients ≥65 years vs. 55·4% <65 and a UK 
series of older symptomatic patients found 67% had extracolonic abnormalities.
7
  
 
The E-RADS classification
17
 aims to clarify management by estimating the clinical significance 
of extracolonic findings. A study of 2,277 screenees found that while 46% had at least one 
extracolonic finding, only 11% were E3/E4,
9
 approximately half the rate we observed and 
suggesting that CTC may have particular utility in symptomatic patients. While E3/E4 CTC 
findings may warrant further investigation, we found approximately 40% were not referred. 
Indeed, nearly one-quarter of E4 lesions were not pursued further, despite this category 
describing a lesion that is “potentially important”. There may be several explanations for this 
observation. Firstly, there are no comprehensive classification tables that describe exactly 
what qualifies as an E4 lesion, or indeed any E category. Therefore, the precise E category 
ascribed depends not on the lesion itself but on its perceived importance according to the 
interpreting radiologist. Perceived importance may differ when the lesion is considered by 
the gastroenterologist or surgeon in charge of the patient’s care. For example, in a 
symptomatic context, the clinician in charge may decide that the lesions does not warrant 
further investigation because it is unlikely to explain the patient’s symptoms. It is also 
possible that the patient may be too ill, too frail and/or unwilling to have an incidental 
extracolonic finding investigated further.  
 
Concerning additional procedures performed to diagnose and/or treat extracolonic findings 
that arose directly from the allocated procedure, in both trials we found that CTC generated 
many more procedures than either BE or colonoscopy; CTC generated approximately 20 
times the number of individual procedures than generated by BE whereas colonoscopy 
generated none. Furthermore, investigation of incidental extracolonic lesions was not 
straightforward, with a third of the patients investigated needing two or more procedures. 
This also impacted on costs. Our simple analysis of unit costs found that patients allocated 
CTC generated on average approximately 20 times the additional costs needed to 
investigate extracolonic findings than BE (99.10 GBP per-patient vs. 4.63 GBP respectively). 
In the colonoscopy trial, on average the costs required to investigate extracolonic findings 
was 152.98 GBP per-patient as opposed to nil for colonoscopy. These figures are in 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
13
accordance with previous work that found the mean cost required to investigate unexpected 
extracolonic findings was approximately equal to the cost of the initial CTC
3
. Our study was 
performed in the National Health Service (NHS), which is funded by the Government via 
general taxation. Costs will differ in  other healthcare systems.  
 
We hypothesised that CTC would accelerate diagnosis of extracolonic cancer compared with 
BE or colonoscopy. Although we found extracolonic cancer was diagnosed at approximately 
double the expected rate 1-year post-randomisation, this applied to all procedures. This 
observation suggests that patients initially allocated BE or colonoscopy undergo further 
abdomino-pelvic investigation, presumably requested to investigate persistent abdominal 
symptoms that have not been clarified by the initial diagnostic procedure, and that this 
ultimately culminates in diagnosis of extracolonic cancer in some patients. Although we 
collected details of procedures arising directly from the randomized examination, we did not 
identify procedures carried out later once the diagnostic episode “on trial” had closed. We 
therefore do not know how often such procedures occur although our data suggest it is 
frequent. Furthermore, analysis of registry data will not identify the time of diagnosis 
precisely; it is possible that CTC may accelerate diagnosis by months, which may not have 
clinical impact ultimately but is likely to be highly desirable to both patients and policy-
makers. We did not have ethical permission to obtain local data on tumour stage but it is 
likely that a significant proportion of the extracolonic cancers were incidental and their 
detection equivalent to “screening” rather than them being responsible for patients’ 
presenting symptoms. Factoring in subsequent abdomino-pelvic investigation for patients 
initially allocated BE or colonoscopy will also increase the cost of follow-up in these patients 
relative to CTC. Because of this, it is highly likely that the mean costs attributed by us to 
investigation by BE and colonoscopy are grossly underestimated and we are seeking ethical 
permission currently to retrieve more comprehensive data regarding this.  
 
We attempted to address whether extracolonic findings underpinned patients’ symptoms: 
3% patients having CTC in the BE trial and 4% in the colonoscopy trial had symptoms 
ultimately attributed to extracolonic pathology, a higher proportion than patients having BE 
(0·2%) or colonoscopy (0·1%). However association between specific reported symptoms 
and extra-colonic disease was generally low, limiting utility for individual patients. Although 
we believed we might identify symptoms associated with extracolonic disease, anaemia was 
the only symptom significantly associated with reporting of an extracolonic finding.  While 
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particular constellations of extracolonic finding with symptoms, age, and sex may predict 
those in need of extra-colonic investigation, this requires complex multi-variate analysis. 
 
Our study has limitations. As noted already, the E-RADS categories describe screening rather 
than symptomatic investigation
17
 and a lack of comprehensive classification tables means 
the score attributed is dependent on the subjective opinion of the radiologist interpreting 
the study. 45 radiologists interpreted CTC and their personal thresholds for reporting 
extracolonic findings will differ, especially for those perceived as low-risk. We did not 
analyse centre-to-centre variation but the pragmatic design suggests our findings are 
generalisable. Patients with proven colorectal cancer were excluded because this diagnosis 
overwhelms others, influencing subsequent investigations. Although some patients may 
have both colorectal and extracolonic cancer, numbers will be small. There were several 
patients registered who were not ultimately randomized, the large majority being a result of 
clinician-declined consent rather than patient-declined consent (Appendix Table 1). The 
commonest single reason given was that the clinician held a strong a priori belief that 
colonoscopy should be performed (731 patients), followed by CT (303 patients), and flexible 
sigmoidoscopy (230 patients). Our publications detailing analysis of the primary outcome 
(detection of colorectal cancer and large polyps) compared included and excluded patients 
as is standard practice for randomized controlled trials. We found that patients included in 
both trials were significantly more likely to be younger than excluded patients. In the BE trial 
we found patients were also more likely to be female, to present with abdominal pain or 
change in bowel habit, and were less likely to present with rectal bleeding, anaemia, or 
weight loss.
22
 In the colonoscopy trial we found patients were also more likely to be male, to 
present with a change in bowel habit, rectal bleeding, or abdominal pain and were less likely 
to present with anaemia.
16
 A similar comparison was not possible in the present paper since 
we focus on extracolonic pathology detected in patients without colorectal cancer: The 
proportion of excluded patients without colorectal cancer is unknown, with the result that a 
similar comparison would not be statistically valid. 
 
We intend to model the impact of extracolonic detections on lives saved versus 
morbidity/mortality due to unnecessary investigation. While the present focus is on 
extracolonic tumours, benign pathology is important; CTC is regarded as “highly cost-
effective” for abdominal aortic aneurysm.
23
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In summary, extracolonic findings are identified commonly by radiologists reporting CTC in 
symptomatic patients. In this trial, approximately 8% of symptomatic patients having CTC 
were investigated for extracolonic findings, which explained symptoms in approximately 4%. 
Extracolonic malignancy was found in 1·6% but time to diagnosis was not reduced compared 
to BE or colonoscopy at 1- or 3- years. 
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Legends for Illustrations: 
 
 
 
Figure 1: Patient flow through the trial. 
 
Figure 2: Kaplan-Meier plots of the cumulative incidence of extracolonic cancer in the two trials:  1-
year post-randomisation in the barium enema trial (A) and colonoscopy trial (B) and 3-years post-
randomisation in the barium enema trial (C) and colonoscopy trial (D). 
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Table 1: E-RADS category, referral for further procedures and most invasive procedure performed for all individual extracolonic findings by diagnostic pathway and 
randomized procedure* 
 
 
CT colonography (CTC) vs. barium enema (BE) trial 
CT colonography (CTC) vs. 
colonoscopy trial§ 
BE performed 
(n=2223) 
CTC  performed 
(n=1161) 
CTC  performed 
(n=473) 
Extracolonic 
findings reported 
Extracolonic 
findings referred 
for further 
procedures† 
Extracolonic 
findings 
reported 
Extracolonic 
findings referred 
for further 
procedures † 
Extracolonic 
findings reported 
Extracolonic 
findings referred 
for further 
procedures † 
n 
rate 
(/1000) n 
rate 
(/1000) n 
rate 
(/1000) n 
rate 
(/1000) n 
rate 
(/1000) n 
rate 
(/1000) 
E-RADS category  
  
 
   
 
     
E4 6 2.7 4 1.8 53 45.6 38 32.7 23 48.6 20 42.3 
E3 7 3.1 0 0 243 209.3 40 34.5 87 183.9 17 35.9 
E2 33 14.8 2 0.9 932 802.8 11 9.5 425 898.5 12 25.4 
E1 0 0 0 0 18 15.5 0 0 3 6.3 0 0 
Most invasive procedure performed as 
a result of finding       
 
     
Surgical 
 - 3 1.3  - 19 16.4  - 12 25.4 
Invasive, non-surgical 
 - 2 0.9  - 23 19.8  - 13 27.5 
Non-invasive imaging 
 - 1 0.4  - 45 38.8  - 23 48.6 
Other‡ 
 - 0 0  - 2 1.7  - 1 2.1 
 
*subjects could have multiple extracolonic findings reported. 
†two patients had two unrelated findings investigated and included in the table. 
‡includes two blood tests and one urine test. 
§no patient having colonoscopy had an extracolonic finding reported. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 2: Proportion of patients* with at least one extracolonic finding at randomized procedure, the proportion referred for further investigation as a 
consequence of an extracolonic finding, the proportion in whom a diagnosis was made, and the proportion who had presenting symptoms attributable to the 
diagnosis. 
 
 
CT colonography (CTC) vs. barium enema (BE) trial CT colonography (CTC) vs. colonoscopy trial 
 
BE CTC CTC 
Characteris
tic 
BE 
perfor
med 
≥1 
extracol
onic 
finding 
Referred 
for 
investigat
ion 
Received 
extracolo
nic 
diagnosi
s  
≥1 
sympto
m 
attributa
ble to  
diagnosi
CTC 
perfor
med 
≥1 
extracol
onic 
finding 
Referred 
for 
investigat
ion 
Received 
extracolo
nic 
diagnosi
s  
≥1 
sympto
m 
attributa
ble to  
diagnosi
CTC 
perfor
med 
≥1 
extracol
onic 
finding 
Referred 
for 
investigat
ion 
Received 
extracolo
nic 
diagnosi
s  
≥1 
sympto
m 
attributa
ble to  
diagnosi
 
 n % n % n % n %  n % n % n % n %  n % n % n % n % 
Total 2223 42 1.9 6 0.3 5 0.2 4 0.2 1161 672 57.9 88 8 79 7 33 3 473 287 60.7 48 1 42 9 17 4 
Sex 
        
                   
Male 860 15 1.7 3 0.3 2 0.2 2 0.2 441 259 58.7 36 8 34 8 14 3 212 126 59.4 19 9 16 8 4 2 
Female 1363 27 2.0 3 0.2 3 0.2 2 0.1 720 413 57.4 52 7 45 6 19 3 261 161 61.7 29 1 26 1 13 5 
Age 
 
        
 
                 
55-64 760 7 0.9 2 0.3 2 0.3 1 0.1 385 185 48.1 25 6 22 6 7 2 201 112 55.7 20 1 18 9 10 5 
65-74 871 13 1.5 1 0.1 1 0.1 1 0.1 451 258 57.2 30 7 28 6 14 3 164 94 57.3 17 1 13 8 4 2 
75-84 542 22 4.1 3 0.6 2 0.4 2 0.4 290 203 70.0 29 10 25 9 9 3 98 72 73.5 10 1 10 1 2 2 
85+ 50 0 0 0 0 0 0 0 0 35 26 74.3 4 11 4 1 3 9 10 9 90.0 1 1 1 1 1 1
Symptoms/
                           
Change in 1698 33 1.9 5 0.3 4 0.2 3 0.2 903 515 57.0 65 7 58 6 21 2 343 215 62.7 34 1 30 9 11 3 
Rectal 664 11 1.7 0 0 0 0 0 0 345 198 57.4 21 6 18 5 4 1 210 126 60.0 24 1 22 1 9 4 
Abdomina 728 12 1.7 3 0.4 3 0.4 3 0.4 376 213 56.7 28 7 27 7 20 5 108 64 59.3 14 1 13 1 11 1
Anaemia 250 9 3.6 1 0.4 1 0.4 1 0.4 129 93 72.1 15 12 14 1 8 6 48 33 68.7 7 1 6 1 1 2 
Weight 283 5 1.8 2 0.7 2 0.7 2 0.7 168 105 62.5 18 11 16 1 5 3 69 45 65.2 9 1 9 1 3 4 
Other 257 4 1.6 2 0.8 1 0.4 1 0.4 123 68 55.3 9 7 7 6 4 3 91 54 59.3 10 1 9 1 5 5 
 
*Patients with CRC diagnosed were excluded. 
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Table 3: Final diagnosis of extracolonic neoplasms by ICD-10 category. 
 
 
CT colonography (CTC) vs. barium enema (BE) 
trial 
CT colonography 
(CTC) vs. 
colonoscopy trial 
BE CTC CTC 
# patients 
diagnosed 
# patients 
with ≥1 
symptom 
related to 
diagnosis 
#patients 
diagnosed 
# patients 
with ≥1 
symptom 
related to 
diagnosis 
#patients 
diagnosed 
# patients 
with ≥1 
symptom 
related to 
diagnosis 
Malignant neoplasms 
 
     
C64 Malignant neoplasm of kidney, except renal pelvis        4 3 3 2 
C25 Malignant neoplasm of pancreas          
 
 2 2 1 1 
C61 Malignant neoplasm of prostate         1 1 2 2   
C34 Malignant neoplasm of bronchus and lung         
 
 1 1 1  
C78 Secondary malignant neoplasm of respiratory 
and digestive organs   1 1 1 1 
C82 Follicular [nodular] non-Hodgkin's lymphoma         1    1 1 
C16 Malignant neoplasm of stomach         
 
   1 1 
C17 Malignant neoplasm of small intestine 
 
 1 1   
C22 Malignant neoplasm of liver and intrahepatic bile ducts     1 1   
C48 Malignant neoplasm of retroperitoneum and peritoneum 1 1     
C56 Malignant neoplasm of ovary          
 
 1 1   
C65 Malignant neoplasm of renal pelvis   
 
   1 1 
C77 Secondary and unspecified malignant 
neoplasm of lymph nodes      1 1 
C80 Malignant neoplasm without specification of 
site           1 1   
C90 Multiple myeloma and malignant plasma cell 
neoplasms     1 1 
C92 Myeloid leukaemia 
 
 1 1   
Total: 3 2 15 14 11 9 
Benign neoplasms 
 
     
D27.0 Benign neoplasm of ovary 
 
 10 5 6 2 
D18.0 Haemangioma, any site 
 
 8  2  
D14.3 Benign neoplasm of bronchus and lung 
 
 3  3  
D25.9 Leiomyoma of uterus, unspecified 
 
 4 3 1 1 
D30.0 Benign neoplasm of kidney 
 
 3  1  
D35.0 Benign neoplasm of adrenal gland 
 
 1  1  
D13.6 Benign neoplasm of pancreas 
 
   1 1 
D36.1 Benign neoplasm of peripheral nerves and 
autonomic nervous system   1    
D44.1 Neoplasm of uncertain or unknown behaviour 
of adrenal gland     1 1 
Total: 0  30 8 16 5 
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Table 4:  Extracolonic cancers diagnosed within one year of randomisation by ICD10 code for BE trial 
and colonoscopy trial.  
 
Barium enema trial Colonoscopy trial 
CT 
colonography 
(CTC) 
(n=1277) 
Barium enema 
(BE) 
(n=2527) 
CT 
colonography 
(CTC) 
(n=533) 
Colonoscopy 
(csy) 
(n=1047) 
Total 
Found 
by 
CTC† Total 
Found 
by 
BE 
 
Total 
Found 
by 
CTC† 
Total 
Found 
by 
csy 
 
All extracolonic cancers* 27 9 67‡ 3  16 9 32 0  
Person-years of follow-up§ 1259  2489   523  1030   
Incidence (per 1000 person-years) 21.4  26.9   30.6  31.1    
Cancer type (ICD-10)           
Stomach (C16) 0  5   2 1 1   
Small Intestine (C17) 0  2   1  1   
Hepatobiliary system (C22, C24) 0  2   1  1   
Pancreas (C25) 3 2 7   1 1 6   
Digestive organs, other and ill 
defined (C26) 0  0        
Bronchus and lung (C34) 5 1 9   2 1 7   
Mesothelial and soft tissue (C45, 
C46, C48) 3 1 2 1       
Breast (C50) 3  6     4   
Cervix uteri (C53)   1        
Ovary (C56) 2 1 4        
Prostate (C61) 4 1 10 1    4   
Kidney (C64, C65) 2 2 3   5 4 3   
Bladder (C67)   1   1     
Lymphoid or haematopoietic 
tissue 
(C81, C82, C83, C85, C90, C91, 
C92) 
2  6 1  2 2 1   
Primary site unknown (C80) 2 1 3        
Other¶ 1  6   1  4   
 
Data are number, unless otherwise specified.  
*All primary malignant neoplasms, excluding colorectal cancers (C18-C20) and non-melanoma malignant neoplasms 
of the skin (C44). Patients could have more than one cancer diagnosed.  
†Comparison with the malignancies reported in Table 4: barium enema trial - eight malignancies were included in 
both tables, two malignancies from Table 4 were excluded from Table 5 as were diagnosed later than one year after 
randomisation, one secondary cancer from Table 4 was excluded from Table 5, four extracolonic cancers detected by 
CT colonography but not verified by the NHS Information Centre were included in Table 4 but excluded from Table 5 
and one malignancy diagnosed in a subject also diagnosed with colorectal cancer in Table 5 was excluded from 
Table 4; colonoscopy trial – two secondary cancers from Table 4 were excluded from Table 5.  
‡One patient assigned to barium enema had two extracolonic cancers diagnosed within 1 year: melanoma of skin 
and lymphoid leukaemia. No patients assigned to CT colonography in the barium enema trial had more than one 
extracolonic cancer diagnosed.  
§Adjusted for reported mortality. ¶Comprises cancers of the oesophagus (C15); malignant melanoma of the skin 
(C43); vulva (C51); spinal cord, cranial nerves and other parts of central nervous system (C72); thyroid (C73); and 
other and ill-defined sites (C76). 
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Table 5: Extracolonic cancers diagnosed within 3 years of randomisation by ICD10 code for BE trial and 
colonoscopy trial. 
 
Barium enema trial Colonoscopy trial 
CT 
colonography 
(CTC) 
(n=1277) 
Barium enema 
(BE) 
(n=2527) 
CT 
colonography 
(CTC) 
(n=533) 
Colonoscopy 
(csy) 
(n=1047) 
Total 
Found 
by 
CTC† Total 
Found 
by 
BE 
 
Total 
Found 
by 
CTC† 
Total 
Found 
by 
csy 
 
All extracolonic cancers* 78 11 132‡ 3  27 9 55§ 0  
Person-years of follow-up¶ 3663  7275   1536  2992   
Incidence (per 1000 person-years) 21.3  18.1   17 .6  18.4   
Cancer type (ICD-10)           
Stomach (C16) 3  10   4 1 3   
Small Intestine (C17) 0  3   1  1   
Hepatobiliary system (C22, C24) 2 1 3   1  4   
Pancreas (C25) 5 2 9   2 1 7   
Digestive organs, other and ill 
defined (C26) 0  1        
Bronchus and lung (C34) 17 1 23   2 1 11   
Mesothelial and soft tissue 
(C45, C46, C48) 3 1 5 1    1   
Breast (C50) 14  14   2  7   
Cervix uteri (C53)   1        
Ovary (C56) 2 1 4    1     
Prostate (C61) 7 1 20 1   3  10   
Kidney (C64, C65) 4 3 6   5 4 4   
Bladder (C67)   4   2     
Lymphoid or haematopoietic 
tissue 
(C81, C82, C83, C85, C90, C91, 
C92) 
7  12 1  2 2 3   
Primary site unknown (C80) 5 1 3        
Other|| 9  14   2  4   
 
Data are number, unless otherwise specified. *All primary malignant neoplasms, excluding 
colorectal cancers (C18-C20) and non-melanoma malignant neoplasms of the skin (C44). Patients 
could have more than one cancer diagnosed. † Comparison with the malignancies reported in Table 
4: barium enema trial - ten malignancies were included in both tables, one secondary cancer from 
Table 4 was excluded from Table 6, four extracolonic cancers detected by CT colonography but not 
verified by the NHS Information Centre were included in Table 4 but excluded from Table 6 and one 
malignancy diagnosed in a subject also diagnosed with colorectal cancer in Table 6 was excluded 
from Table 4; colonoscopy trial – two secondary cancers from Table 4 were excluded from Table 6.  
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‡Four patients assigned to barium enema had two extracolonic cancers diagnosed within 36 
months: one stomach and prostate; one small intestine and biliary tract; one melanoma of skin and 
lymphoid leukaemia; one prostate and bladder. No patients assigned to CT colonography in the 
barium enema trial had more than one extracolonic cancer diagnosed. §One patient assigned to 
colonoscopy had two extracolonic cancers diagnosed within 36 months: lung and kidney cancer. No 
patients assigned to CT colonography in the colonoscopy trial had more than one extracolonic 
cancer diagnosed. ¶Adjusted for reported mortality. ||Comprises cancers of other and unspecified 
parts of the tongue (C02); oesophagus (C15); bone and articular cartilage of other and unspecified 
sites (C41); malignant melanoma of the skin (C43); vulva (C51); brain (C71); spinal cord, cranial 
nerves and other parts of central nervous system (C72); thyroid (C73); and other and ill-defined sites 
(C76).  
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SUPPORTING DOCUMENT: APPENDICES 
Appendix table 1: Reasons for exclusions 
 
REASON n (%) 
Clinician reasons for declining consent 
Colorectal or other cancer already diagnosed   
Colorectal cancer diagnosed 56 1.8 
Other cancer diagnosed 69 2.2 
Specific procedure requested   
Colonoscopy 731 23.6 
CT 303 9.8 
Flexible sigmoidoscopy 230 7.4 
Oesophagogastroduodenoscopy 218 7.0 
Barium enema 19 0.6 
Ultrasound 16 0.5 
Magnetic resonance imaging 5 0.2 
Unknown 39 1.3 
Clinical situation too urgent or waiting list too long 52 1.7 
Patient unfit for whole colon examination 215 6.9 
Patient unable to give informed consent 75 2.4 
No reason given 148 4.7 
Total where clinician declined consent 2,176 70.2 
Patient reasons for declining consent 
Patient wanted a specific procedure:   
Colonoscopy 15 0.5 
CT 3 0.1 
Barium enema 2 0.06 
Unknown 128 4.1 
Patient did not want a specific procedure:   
CT as claustrophobic 13 0.4 
CT for other reasons 2 0.06 
Colonoscopy 1 0.03 
Barium enema 1 0.03 
Patient had difficulty comprehending 84 2.7 
Patient died before consent obtained 2 0.06 
No reason given 583 18.8 
Total where patient declined consent 834 26.9 
Reason for exclusion unknown 26 0.8 
Patient withdrew consent following randomisation 64 2.1 
TOTAL EXCLUDED 3,100 100.0 
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Appendix table 2: Baseline demographic and clinical characteristics of patients with symptoms of colorectal 
cancer in whom CTC was performed. Patients ultimately found to have colorectal cancer are excluded. 
 
Characteristic. 
CT colonography (CTC) vs. 
barium enema (BE) trial 
CT colonography (CTC) vs. 
colonoscopy trial 
BE 
performed 
(n=2223) 
CTC  
performed 
(n=1161) 
CTC 
performed 
(n=473) 
Colonoscopy  
performed 
(n=908) 
 n % n % n % n % 
Sex 
        
Male 860 39 441 38 212 45 402 44 
Female 1363 61 720 62 261 55 506 56 
Age 
    
    
55-64 760 34 385 33 201 42 350 39 
65-74 871 39 451 39 164 35 330 36 
75-84 542 24 290 25 98 21 206 23 
85+ 50 2 35 3 10 2 22 2 
Symptoms† 
    
    
Change in bowel habit 1698 76 903 78 343 73 679 75 
Harder, less frequent 278 13 143 12 60 13 105 12 
Looser, more frequent 905 41 503 43 191 40 372 41 
Variable frequency 210 9 106 9 47 10 109 12 
Unspecified 305 14 151 13 45 10 93 10 
Rectal bleeding 664 30 345 30 210 44 361 40 
Abdominal pain 728 33 376 32 108 23 199 22 
Anaemia 250 11 129 11 48 10 109 12 
Weight loss 283 13 168 15 69 15 129 14 
Other symptoms 257 12 123 11 91 19 151 17 
† patients may have reported multiple symptoms/signs. 
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Appendix table 3: Non-neoplastic extracolonic findings on barium enema and comparative rates for CT 
colonography. 
 
Finding* 
CT colonography vs. barium 
enema trial 
CT 
colonography 
vs. 
colonoscopy 
trial 
Randomise
d BE 
performed 
(N=2223) 
 
Randomised 
CTC 
performed 
(N=1161) 
 
Randomised  
CTC 
performed 
(N=473) 
 
 n % n % n % 
Hernia (all types) 18 0.8 136 11.7 59 12.5 
Gallstone(s) 3 0.1 88 8 39 8 
Degenerative bone changes 5 0.2 75 6 30 6 
Uterine fibroid(s) 4 0.2 28 2 16 3 
Kidney stone(s) 2 0.09 23 2 5 1 
Splenic cyst(s) 1 0.04 6 0.5 5 1 
Bronchiectasis 1 0.04 8 0.7 2 0.4 
Calcified lymph node(s) 4 0.2 0 0 0 0 
Extrinsic compression 3 0.1 0 0 0 0 
Paget’s disease 1 0.04 1 0.09 1 0.2 
Pericolic abscess 1 0.04 0 0 0 0 
Rectocele 1 0.04 0 0 0 0 
Possible mass in rectrorectal space 1 0.04 0 0 0 0 
Possible prostate cancer with possible 
metastases 1 
0.04 0 0 0 0 
*Subjects may have multiple findings and have findings in more than one category. 
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Appendix table 4: Total number of procedures performed to investigate and/or treat extracolonic findings in 
the 142 individual patients referred. 
 
 
CT colonography vs. barium 
enema trial 
CT 
colonography 
vs. colonoscopy 
trial† 
 
Barium 
enema* 
CT 
colonography† 
CT 
colonography‡ 
 n n n 
Surgical procedures 
   
Radical nephrectomy 0 5 4 
Oophorectomy +/- salpingectomy +/- 
hysterectomy 0 5 2 
Aneurysm repair 0 5 0 
Laparotomy 1 2 1 
Inguinal hernia repair 2 1 0 
Whipple procedure 0 0 1 
Laproscopic cholecystectomy 0 0 1 
Right Upper Lobectomy 0 0 1 
Splenectomy 0 1 0 
Adrenalectomy 0 0 1 
Video-assisted thoracoscopy 0 0 1 
Stent insertion 0 0 1 
Total surgical procedures: 3 19 13 
Non-surgical invasive procedures 
   
Ultrasound transvaginal 0 9 9 
Oesophagogastroduodenoscopy 0 1 5 
Hysteroscopy 0 4 0 
Ultrasound-guided biopsy 0 4 0 
Bronchoscopy 0 2 0 
Lymph node biopsy 0 1 1 
CT-guided biopsy 0 0 2 
Prostate biopsy 1 1 0 
Endoscopic retrograde 
cholangiopancreatography 0 2 0 
Aspiration of fluid from abdomen 1 1 0 
Extracorporeal shock wave lithotripsy 0 1 0 
Flexible cystoscopy 0 1 0 
Fluid aspiration and culture of uterus 0 1 0 
Renal biopsy 0 0 1 
Ultrasound-guided fine needle aspiration of 
pancreas 0 1 0 
Bone marrow biopsy 0 1 0 
Colonoscopy 0 0 1 
Total non surgical, invasive procedures: 2 30 19 
Non invasive imaging procedures 
   
Ultrasound 2 30 10 
CT 1 23 17 
X-ray 3 2 10 
MRI 0 8 5 
Bone scan 1 2 1 
Barium meal 0 1 2 
PET scan lung 0 1 1 
Dimercaptosuccinic acid scan 0 0 1 
Intravenous urogram 0 1 0 
Total non invasive imaging procedures: 7 68 47 
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*Six findings in 6 patients having BE were referred for at least one of the procedures in the table: four patients had one 
procedure performed, one had three performed and one had five performed. 
†87 findings were referred for at least one of the procedures in the table: 64 had one procedure performed, 17 had two 
performed, five had three performed and one had four procedures.  Two other findings were referred but were not included 
in this table; one was only referred for a blood test and one only for a urine test. 
‡48 findings were referred for at least one of the procedures in the table: 29 had one procedure performed, ten had two 
performed, six had three performed and three had four procedures.  One other finding was only referred for a blood test 
and was not included in this table. 
 
 
 
